Marktanalyse - Parkinson's Disease - Pipeline Review, H2 2016

Global Markets Direct
12.2016
879 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Parkinson's Disease - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease — Pipeline Review, H2 2016, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson’s disease. Parkinson’s disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 30, 37, 5, 173, 42 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 50, 15 and 1 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 10

Parkinson's Disease Overview 11

Therapeutics Development 12

Parkinson's Disease - Therapeutics under Development by Companies 14

Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes 30

Parkinson's Disease - Pipeline Products Glance 33

Parkinson's Disease - Products under Development by Companies 37

Parkinson's Disease - Products under Investigation by Universities/Institutes 56

Parkinson's Disease - Companies Involved in Therapeutics Development 60

Parkinson's Disease - Therapeutics Assessment 245

Drug Profiles 274

Parkinson's Disease - Dormant Projects 797

Parkinson's Disease - Discontinued Products 822

Parkinson's Disease - Product Development Milestones 825

Appendix 839





List of Tables

Number of Products under Development for Parkinson's Disease, H2 2016 51

Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2016 52

Number of Products under Development by Companies, H2 2016 53

Number of Products under Development by Companies, H2 2016 (Contd..1) 54

Number of Products under Development by Companies, H2 2016 (Contd..2) 55

Number of Products under Development by Companies, H2 2016 (Contd..3) 56

Number of Products under Development by Companies, H2 2016 (Contd..4) 57

Number of Products under Development by Companies, H2 2016 (Contd..5) 58

Number of Products under Development by Companies, H2 2016 (Contd..6) 59

Number of Products under Development by Companies, H2 2016 (Contd..7) 60

Number of Products under Development by Companies, H2 2016 (Contd..8) 61

Number of Products under Development by Companies, H2 2016 (Contd..9) 62

Number of Products under Development by Companies, H2 2016 (Contd..10) 63

Number of Products under Development by Companies, H2 2016 (Contd..11) 64

Number of Products under Development by Companies, H2 2016 (Contd..12) 65

Number of Products under Development by Companies, H2 2016 (Contd..13) 66

Number of Products under Development by Companies, H2 2016 (Contd..14) 67

Number of Products under Development by Companies, H2 2016 (Contd..15) 68

Number of Products under Investigation by Universities/Institutes, H2 2016 69

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 70

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 71

Comparative Analysis by Late Stage Development, H2 2016 72

Comparative Analysis by Clinical Stage Development, H2 2016 73

Comparative Analysis by Early Stage Development, H2 2016 74

Comparative Analysis by Unknown Stage Development, H2 2016 75

Products under Development by Companies, H2 2016 76

Products under Development by Companies, H2 2016 (Contd..1) 77

Products under Development by Companies, H2 2016 (Contd..2) 78

Products under Development by Companies, H2 2016 (Contd..3) 79

Products under Development by Companies, H2 2016 (Contd..4) 80

Products under Development by Companies, H2 2016 (Contd..5) 81

Products under Development by Companies, H2 2016 (Contd..6) 82

Products under Development by Companies, H2 2016 (Contd..7) 83

Products under Development by Companies, H2 2016 (Contd..8) 84

Products under Development by Companies, H2 2016 (Contd..9) 85

Products under Development by Companies, H2 2016 (Contd..10) 86

Products under Development by Companies, H2 2016 (Contd..11) 87

Products under Development by Companies, H2 2016 (Contd..12) 88

Products under Development by Companies, H2 2016 (Contd..13) 89

Products under Development by Companies, H2 2016 (Contd..14) 90

Products under Development by Companies, H2 2016 (Contd..15) 91

Products under Development by Companies, H2 2016 (Contd..16) 92

Products under Development by Companies, H2 2016 (Contd..17) 93

Products under Development by Companies, H2 2016 (Contd..18) 94

Products under Investigation by Universities/Institutes, H2 2016 95

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 96

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 97

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 98

Parkinson's Disease - Pipeline by 2-BBB Medicines BV, H2 2016 99

Parkinson's Disease - Pipeline by 4P Therapeutics LLC, H2 2016 100

Parkinson's Disease - Pipeline by AbbVie Inc, H2 2016 101

Parkinson's Disease - Pipeline by AC Immune SA, H2 2016 102

Parkinson's Disease - Pipeline by Acelot Inc, H2 2016 103

Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H2 2016 104

Parkinson's Disease - Pipeline by Adamas Pharmaceuticals Inc, H2 2016 105

Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 106

Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd, H2 2016 107

Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 108

Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2016 109

Parkinson's Disease - Pipeline by Amabiotics SAS, H2 2016 110

Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 111

Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H2 2016 112

Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H2 2016 113

Parkinson's Disease - Pipeline by Angita BV, H2 2016 114

Parkinson's Disease - Pipeline by Antoxis Ltd, H2 2016 115

Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016 116

Parkinson's Disease - Pipeline by APeT Holding BV, H2 2016 117

Parkinson's Disease - Pipeline by ApoPharma Inc, H2 2016 118

Parkinson's Disease - Pipeline by Aposense Ltd, H2 2016 119

Parkinson's Disease - Pipeline by Araclon Biotech SL, H2 2016 120

Parkinson's Disease - Pipeline by ArmaGen Inc, H2 2016 121

Parkinson's Disease - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 122

Parkinson's Disease - Pipeline by AstraZeneca Plc, H2 2016 123

Parkinson's Disease - Pipeline by AudioCure Pharma GmbH, H2 2016 124

Parkinson's Disease - Pipeline by Berg LLC, H2 2016 125

Parkinson's Disease - Pipeline by Bial - Portela & Ca SA, H2 2016 126

Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H2 2016 127

Parkinson's Disease - Pipeline by BioArtic AB, H2 2016 128

Parkinson's Disease - Pipeline by Biogen Inc, H2 2016 129

Parkinson's Disease - Pipeline by BioHealthonomics Inc, H2 2016 130

Parkinson's Disease - Pipeline by Biopharm GmbH, H2 2016 131

Parkinson's Disease - Pipeline by Biotie Therapies Corp, H2 2016 132

Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 133

Parkinson's Disease - Pipeline by Calico LLC, H2 2016 134

Parkinson's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H2 2016 135

Parkinson's Disease - Pipeline by Cardax Inc, H2 2016 136

Parkinson's Disease - Pipeline by Carna Biosciences Inc, H2 2016 137

Parkinson's Disease - Pipeline by Cell Cure Neurosciences Ltd, H2 2016 138

Parkinson's Disease - Pipeline by Cellceutix Corp, H2 2016 139

Parkinson's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2016 140

Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H2 2016 141

Parkinson's Disease - Pipeline by Clera Inc, H2 2016 142

Parkinson's Disease - Pipeline by Clevexel Pharma SA, H2 2016 143

Parkinson's Disease - Pipeline by Contera Pharma ApS, H2 2016 144

Parkinson's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 145

Parkinson's Disease - Pipeline by Corium International Inc, H2 2016 146

Parkinson's Disease - Pipeline by Curemark LLC, H2 2016 147

Parkinson's Disease - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 148

Parkinson's Disease - Pipeline by Denali Therapeutics Inc, H2 2016 149

Parkinson's Disease - Pipeline by Depomed Inc, H2 2016 150

Parkinson's Disease - Pipeline by DermaXon LLC, H2 2016 151

Parkinson's Disease - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 152

Parkinson's Disease - Pipeline by Dizlin Medical Design AB, H2 2016 153

Parkinson's Disease - Pipeline by Domain Therapeutics SA, H2 2016 154

Parkinson's Disease - Pipeline by Edison Pharmaceuticals Inc, H2 2016 155

Parkinson's Disease - Pipeline by Eli Lilly and Company, H2 2016 156

Parkinson's Disease - Pipeline by Ensemble Therapeutics Corp, H2 2016 157

Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2016 158

Parkinson's Disease - Pipeline by FPRT Bio Inc, H2 2016 159

Parkinson's Disease - Pipeline by Genecode AS, H2 2016 160

Parkinson's Disease - Pipeline by Generon (Shanghai) Corp Ltd, H2 2016 161

Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 162

Parkinson's Disease - Pipeline by GenKyoTex SA, H2 2016 163

Parkinson's Disease - Pipeline by Genmab A/S, H2 2016 164

Parkinson's Disease - Pipeline by Genosco Inc, H2 2016 165

Parkinson's Disease - Pipeline by Genzyme Corp, H2 2016 166

Parkinson's Disease - Pipeline by H. Lundbeck A/S, H2 2016 167

Parkinson's Disease - Pipeline by Harbor Therapeutics Inc, H2 2016 168

Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd, H2 2016 169

Parkinson's Disease - Pipeline by Herantis Pharma Plc, H2 2016 170

Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016 171

Parkinson's Disease - Pipeline by Horizon Pharma Plc, H2 2016 172

Parkinson's Disease - Pipeline by Huons Co Ltd, H2 2016 173

Parkinson's Disease - Pipeline by ICB International Inc, H2 2016 174

Parkinson's Disease - Pipeline by Immungenetics AG, H2 2016 175

Parkinson's Disease - Pipeline by Impel NeuroPharma Inc, H2 2016 176

Parkinson's Disease - Pipeline by Intec Pharma ltd, H2 2016 177

Parkinson's Disease - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 178

Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H2 2016 179

Parkinson's Disease - Pipeline by International Stem Cell Corp, H2 2016 180

Parkinson's Disease - Pipeline by Io Therapeutics Inc, H2 2016 181

Parkinson's Disease - Pipeline by Iproteos SL, H2 2016 182

Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 183

Parkinson's Disease - Pipeline by Kainos Medicine Inc, H2 2016 184

Parkinson's Disease - Pipeline by Khondrion BV, H2 2016 185

Parkinson's Disease - Pipeline by KineMed Inc, H2 2016 186

Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 187

Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 188

Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H2 2016 189

Parkinson's Disease - Pipeline by Living Cell Technologies Ltd, H2 2016 190

Parkinson's Disease - Pipeline by Longevity Biotech Inc, H2 2016 191

Parkinson's Disease - Pipeline by Luye Pharma Group Ltd, H2 2016 192

Parkinson's Disease - Pipeline by Lysosomal Therapeutics Inc, H2 2016 193

Parkinson's Disease - Pipeline by M et P Pharma AG, H2 2016 194

Parkinson's Disease - Pipeline by M's Science Corp, H2 2016 195

Parkinson's Disease - Pipeline by M3 Biotechnology Inc, H2 2016 196

Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc, H2 2016 197

Parkinson's Disease - Pipeline by MedImmune LLC, H2 2016 198

Parkinson's Disease - Pipeline by MeiraGTx Ltd, H2 2016 199

Parkinson's Disease - Pipeline by Merck & Co Inc, H2 2016 200

Parkinson's Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2016 201

Parkinson's Disease - Pipeline by Minerva Neurosciences Inc, H2 2016 202

Parkinson's Disease - Pipeline by Mission Therapeutics Ltd, H2 2016 203

Parkinson's Disease - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 204

Parkinson's Disease - Pipeline by MitoDys Therapeutics Ltd, H2 2016 205

Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H2 2016 206

Parkinson's Disease - Pipeline by Netherlands Translational Research Center BV, H2 2016 207

Parkinson's Disease - Pipeline by Neuralstem Inc, H2 2016 208

Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2016 209

Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 210

Parkinson's Disease - Pipeline by NeuroDerm Ltd, H2 2016 211

Parkinson's Disease - Pipeline by NeuroNascent Inc, H2 2016 212

Parkinson's Disease - Pipeline by NeurOp Inc, H2 2016 213

Parkinson's Disease - Pipeline by Neuropore Therapies Inc, H2 2016 214

Parkinson's Disease - Pipeline by New World Laboratories Inc, H2 2016 215

Parkinson's Disease - Pipeline by Newron Pharmaceuticals SpA, H2 2016 216

Parkinson's Disease - Pipeline by nLife Therapeutics SL, H2 2016 217

Parkinson's Disease - Pipeline by NLS Pharma Group, H2 2016 218

Parkinson's Disease - Pipeline by Novartis AG, H2 2016 219

Parkinson's Disease - Pipeline by Novo Nordisk A/S, H2 2016 220

Parkinson's Disease - Pipeline by NsGene A/S, H2 2016 221

Parkinson's Disease - Pipeline by Omeros Corp, H2 2016 222

Parkinson's Disease - Pipeline by Oncodesign SA, H2 2016 223

Parkinson's Disease - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 224

Parkinson's Disease - Pipeline by OPKO Health Inc, H2 2016 225

Parkinson's Disease - Pipeline by Orion Oyj, H2 2016 226

Parkinson's Disease - Pipeline by Oryzon Genomics SA, H2 2016 227

Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H2 2016 228

Parkinson's Disease - Pipeline by ParkCell AB, H2 2016 229

Parkinson's Disease - Pipeline by Peptron Inc, H2 2016 230

Parkinson's Disease - Pipeline by Pfizer Inc, H2 2016 231

Parkinson's Disease - Pipeline by Pharma Two B Ltd, H2 2016 232

Parkinson's Disease - Pipeline by PharmatrophiX Inc, H2 2016 233

Parkinson's Disease - Pipeline by Pharmaxis Ltd, H2 2016 234

Parkinson's Disease - Pipeline by Pharmicell Co Ltd, H2 2016 235

Parkinson's Disease - Pipeline by Pharnext SA, H2 2016 236

Parkinson's Disease - Pipeline by Phenomenome Discoveries Inc, H2 2016 237

Parkinson's Disease - Pipeline by Plex Pharmaceuticals Inc, H2 2016 238

Parkinson's Disease - Pipeline by Prana Biotechnology Ltd, H2 2016 239

Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H2 2016 240

Parkinson's Disease - Pipeline by Primary Peptides Inc, H2 2016 241

Parkinson's Disease - Pipeline by Proclara Biosciences Inc, H2 2016 242

Parkinson's Disease - Pipeline by Promentis Pharmaceuticals Inc, H2 2016 243

Parkinson's Disease - Pipeline by Promius Pharma LLC, H2 2016 244

Parkinson's Disease - Pipeline by Proteostasis Therapeutics Inc, H2 2016 245

Parkinson's Disease - Pipeline by Prothena Corp Plc, H2 2016 246

Parkinson's Disease - Pipeline by QR Pharma Inc, H2 2016 247

Parkinson's Disease - Pipeline by reMYND NV, H2 2016 248

Parkinson's Disease - Pipeline by Retrotope Inc, H2 2016 249

Parkinson's Disease - Pipeline by Sage Therapeutics Inc, H2 2016 250

Parkinson's Disease - Pipeline by Saje Pharma LLC, H2 2016 251

Parkinson's Disease - Pipeline by SanBio Inc, H2 2016 252

Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 253

Parkinson's Disease - Pipeline by Saniona AB, H2 2016 254

Parkinson's Disease - Pipeline by Sellas Inc, H2 2016 255

Parkinson's Disease - Pipeline by Serina Therapeutics Inc, H2 2016 256

Parkinson's Disease - Pipeline by Shire Plc, H2 2016 257

Parkinson's Disease - Pipeline by Sigma-Tau SpA, H2 2016 258

Parkinson's Disease - Pipeline by SignPath Pharma Inc, H2 2016 259

Parkinson's Disease - Pipeline by Signum Biosciences Inc, H2 2016 260

Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 261

Parkinson's Disease - Pipeline by STATegics Inc, H2 2016 262

Parkinson's Disease - Pipeline by Stelic Institute & Co Inc, H2 2016 263

Parkinson's Disease - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 264

Parkinson's Disease - Pipeline by Sunovion Pharmaceuticals Inc, H2 2016 265

Parkinson's Disease - Pipeline by Synthonics Inc, H2 2016 266

Parkinson's Disease - Pipeline by Takara Bio Inc, H2 2016 267

Parkinson's Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 268

Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H2 2016 269

Parkinson's Disease - Pipeline by TechnoPhage SA, H2 2016 270

Parkinson's Disease - Pipeline by Teikoku Pharma USA Inc, H2 2016 271

Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 272

Parkinson's Disease - Pipeline by Titan Pharmaceuticals Inc, H2 2016 273

Parkinson's Disease - Pipeline by Trevena Inc, H2 2016 274

Parkinson's Disease - Pipeline by TyrNovo Ltd, H2 2016 275

Parkinson's Disease - Pipeline by UniQure NV, H2 2016 276

Parkinson's Disease - Pipeline by Vanton Research Laboratory LLC, H2 2016 277

Parkinson's Disease - Pipeline by Varinel Inc, H2 2016 278

Parkinson's Disease - Pipeline by VistaGen Therapeutics Inc, H2 2016 279

Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 280

Parkinson's Disease - Pipeline by Voyager Therapeutics Inc, H2 2016 281

Parkinson's Disease - Pipeline by vTv Therapeutics Inc, H2 2016 282

Parkinson's Disease - Pipeline by Wellstat Therapeutics Corp, H2 2016 283

Assessment by Monotherapy Products, H2 2016 284

Assessment by Combination Products, H2 2016 285

Number of Products by Stage and Target, H2 2016 287

Number of Products by Stage and Mechanism of Action, H2 2016 298

Number of Products by Stage and Route of Administration, H2 2016 310

Number of Products by Stage and Molecule Type, H2 2016 312

Parkinson's Disease - Dormant Projects, H2 2016 836

Parkinson's Disease - Dormant Projects (Contd..1), H2 2016 837

Parkinson's Disease - Dormant Projects (Contd..2), H2 2016 838

Parkinson's Disease - Dormant Projects (Contd..3), H2 2016 839

Parkinson's Disease - Dormant Projects (Contd..4), H2 2016 840

Parkinson's Disease - Dormant Projects (Contd..5), H2 2016 841

Parkinson's Disease - Dormant Projects (Contd..6), H2 2016 842

Parkinson's Disease - Dormant Projects (Contd..7), H2 2016 843

Parkinson's Disease - Dormant Projects (Contd..8), H2 2016 844

Parkinson's Disease - Dormant Projects (Contd..9), H2 2016 845

Parkinson's Disease - Dormant Projects (Contd..10), H2 2016 846

Parkinson's Disease - Dormant Projects (Contd..11), H2 2016 847

Parkinson's Disease - Dormant Projects (Contd..12), H2 2016 848

Parkinson's Disease - Dormant Projects (Contd..13), H2 2016 849

Parkinson's Disease - Dormant Projects (Contd..14), H2 2016 850

Parkinson's Disease - Dormant Projects (Contd..15), H2 2016 851

Parkinson's Disease - Dormant Projects (Contd..16), H2 2016 852

Parkinson's Disease - Dormant Projects (Contd..17), H2 2016 853

Parkinson's Disease - Dormant Projects (Contd..18), H2 2016 854

Parkinson's Disease - Dormant Projects (Contd..19), H2 2016 855

Parkinson's Disease - Dormant Projects (Contd..20), H2 2016 856

Parkinson's Disease - Dormant Projects (Contd..21), H2 2016 857

Parkinson's Disease - Dormant Projects (Contd..22), H2 2016 858

Parkinson's Disease - Dormant Projects (Contd..23), H2 2016 859

Parkinson's Disease - Dormant Projects (Contd..24), H2 2016 860

Parkinson's Disease - Discontinued Products, H2 2016 861

Parkinson's Disease - Discontinued Products (Contd..1), H2 2016 862

Parkinson's Disease - Discontinued Products (Contd..2), H2 2016 863





List of Figures

Number of Products under Development for Parkinson's Disease, H2 2016 51

Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2016 52

Number of Products under Development by Companies, H2 2016 53

Number of Products under Investigation by Universities/Institutes, H2 2016 69

Comparative Analysis by Late Stage Development, H2 2016 72

Comparative Analysis by Clinical Stage Development, H2 2016 73

Comparative Analysis by Early Stage Products, H2 2016 74

Comparative Analysis by Unknown Stage Development, H2 2016 75

Assessment by Monotherapy Products, H2 2016 284

Assessment by Combination Products, H2 2016 285

Number of Products by Top 10 Targets, H2 2016 286

Number of Products by Stage and Top 10 Targets, H2 2016 286

Number of Products by Top 10 Mechanism of Actions, H2 2016 297

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 297

Number of Products by Top 10 Routes of Administration, H2 2016 309

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 309

Number of Products by Top 10 Molecule Types, H2 2016 311

Number of Products by Stage and Top 10 Molecule Types, H2 2016 311

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus